For systemic use:

• Treatment of serious infections caused by specific susceptible aerobic Gram-negative microorganisms in adults and children with limited antibacterial therapy options.

For inhalation use:

• Chronic respiratory tract infections caused by susceptible Gram-negative bacteria, especially Pseudomonas aeruginosa, in cystic fibrosis patients.

Follow official guidelines for the appropriate use of antibacterial agents.